Who
Dov A. Goldstein
Director
Company insider
Files Form 4 as: Director, Gain Therapeutics; Chief Financial Officer, BioAge Labs; Director, Coya Therapeutics; Director, NeuBase Therapeutics; Director and 10% owner, ADMA Biologics; Director, Esperion Therapeutics; Director, Cempra; CFO and Treasurer, Loxo Oncology.
In numbers
- Trades disclosed
- 132
- Buys
- 8
- Sells
- 12
- Bought
- $26.1M
- Sold
- $63.8M
- Companies
- 9
- Companies where not an officer
- 7
- First trade
- 7 Feb 2012
- Last trade
- 15 Jul 2026
- Last filed
- 17 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Jul 2026filed 17 Jul 2026 | GANX Gain Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 15 Jul 2026filed 17 Jul 2026 | GANX Gain Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 23 Apr 2026filed 24 Apr 2026 | BIOA BioAge LabsBiotechnology | SEC FORM 4 Code M | $16K3,542 at $4.38 | filing |
| 23 Apr 2026filed 24 Apr 2026 | BIOA BioAge Labsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,542 at $0.00 | filing |
| 23 Apr 2026filed 24 Apr 2026 | BIOA BioAge Labsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,542 at $0.00 | filing |
| 23 Apr 2026filed 24 Apr 2026 | BIOA BioAge LabsBiotechnology | SEC FORM 4 Code M | $16K3,542 at $4.38 | filing |
| 1 Mar 2026filed 3 Mar 2026 | BIOA BioAge LabsBiotechnology | SEC FORM 4 Code M | $16K3,542 at $4.38 | filing |
| 1 Mar 2026filed 3 Mar 2026 | BIOA BioAge Labsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,542 at $0.00 | filing |
| 1 Mar 2026filed 3 Mar 2026 | BIOA BioAge Labsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,542 at $0.00 | filing |
| 1 Mar 2026filed 3 Mar 2026 | BIOA BioAge LabsBiotechnology | SEC FORM 4 Code M | $16K3,542 at $4.38 | filing |
| 17 Feb 2026filed 19 Feb 2026 | BIOA BioAge Labsoption or derivative · Biotechnology | SEC FORM 4 Code A | —110,000 at $0.00 | filing |
| 17 Feb 2026filed 19 Feb 2026 | BIOA BioAge Labsoption or derivative · Biotechnology | SEC FORM 4 Code A | —110,000 at $0.00 | filing |
| 1 Feb 2026filed 3 Feb 2026 | BIOA BioAge LabsBiotechnology | SEC FORM 4 Code M | $16K3,541 at $4.38 | filing |
| 1 Feb 2026filed 3 Feb 2026 | BIOA BioAge Labsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,541 at $0.00 | filing |
| 1 Feb 2026filed 3 Feb 2026 | BIOA BioAge Labsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,541 at $0.00 | filing |
| 1 Feb 2026filed 3 Feb 2026 | BIOA BioAge LabsBiotechnology | SEC FORM 4 Code M | $16K3,541 at $4.38 | filing |
| 16 Jan 2026filed 21 Jan 2026 | BIOA BioAge LabsBiotechnology | SEC FORM 4 Code M | $16K3,542 at $4.38 | filing |
| 16 Jan 2026filed 21 Jan 2026 | BIOA BioAge Labsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,542 at $0.00 | filing |
| 16 Jan 2026filed 21 Jan 2026 | BIOA BioAge Labsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,542 at $0.00 | filing |
| 16 Jan 2026filed 21 Jan 2026 | BIOA BioAge LabsBiotechnology | SEC FORM 4 Code M | $16K3,542 at $4.38 | filing |
News
BioAge Labs (NASDAQ:BIOA) & GSK (NYSE:GSK) Head-To-Head AnalysisBIOA · themarketsdaily.com · 16 Oct 2026
0 headlines in the last 90 days name Dov A. Goldstein; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.